Support Alert

UPDATE: Class 4 Medicines Defect Information: Crescent Pharma Ltd, SyreniRing 0.120 mg/0.015 mg per 24 hours, vaginal delivery system

The MHRA has been informed that further batches were released which did not contain the safety information, as detailed in the original class 4 notification. Please see details relating to the original batches and additional batches that are subject to this notification. The PIL link has also been updated.

Further information on the affected batches and advice for healthcare professionals can be found on the MHRA website.


Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.